Stay informed about the latest advancements in treatment options with these newly FDA-approved drugs:
Emrelis (telisotuzumab vedotin-tllv) – Approved on May 14, 2025, for advanced or metastatic non-small cell lung cancer (NSCLC) with high c-Met protein overexpression.
Avmapki Fakzynja Co-Pack (avutometinib + defactinib) – Approved on May 8, 2025, for KRAS-mutated low-grade serous ovarian cancer (LGSOC).
Imaavy (nipocalimab-aahu) – Approved on April 29, 2025, for generalized myasthenia gravis.
Penpulimab-kcqx – Approved on April 23, 2025, for recurrent or metastatic nasopharyngeal carcinoma (NPC) in combination or as monotherapy.
Vanrafia (atrasentan) – Approved on April 2, 2025, for reducing proteinuria in primary IgA nephropathy.
Qfitlia (fitusiran) – Approved on March 28, 2025, for preventing bleeding episodes in hemophilia A or B.
Blujepa (gepotidacin) – Approved on March 25, 2025, for uncomplicated urinary tract infections.
Romvimza (vimseltinib) – Approved on February 14, 2025, for tenosynovial giant cell tumors unamenable to surgery.
Gomekli (mirdametinib) – Approved on February 11, 2025, for symptomatic neurofibromatosis type 1.
Journavx (suzetrigine) – Approved on January 30, 2025, for moderate to severe acute pain.
Grafapex (treosulfan) – Approved on January 21, 2025, for pre-transplant conditioning in AML and MDS.
Datroway (datopotamab deruxtecan-dlnk) – Approved on January 17, 2025, for HR-positive, HER2-negative metastatic breast cancer.
Subscribe for updates and more ...